肿瘤
腫瘤
종류
TUMOR
2009年
12期
1133-1136
,共4页
董昭%李琦%秦庆亮%高勇
董昭%李琦%秦慶亮%高勇
동소%리기%진경량%고용
肺肿瘤%癌%非小细胞肺%立体定向放射治疗%药物疗法%复发%存活率
肺腫瘤%癌%非小細胞肺%立體定嚮放射治療%藥物療法%複髮%存活率
폐종류%암%비소세포폐%입체정향방사치료%약물요법%복발%존활솔
Lung neoplasms%Carcinoma%non-small-cell lung%Stereotactic radiotherapy%Drug therapy%Recurrence%Survival rate
目的:探讨立体定向放射治疗技术结合GP化疗方案(吉西他滨+顺铂)治疗首次放疗后局部复发的非小细胞肺癌患者的疗效.方法:38例首次放疗后局部复发的非小细胞肺癌患者接受立体定向放射治疗,处方剂量为3.00~4.85 Gy/次,每周5次,共8~12次,总疗程2~3周;放疗前基于GP方案化疗2个周期,放疗后再给予GP方案化疗4个周期.结果: 38例患者的近期疗效为完全缓解7例、部分缓解23例,总有效率达到78.95%,6个月的总生存率为71.05%,1年的总生存率为10.53%,中位生存时间为7.8个月.结论:立体定向放射治疗首次放疗后局部复发的非小细胞肺癌显示出良好的近期疗效,患者能够耐受,未见严重的近期放射性损伤.晚期放射性损伤和远期疗效还有待进一步研究.
目的:探討立體定嚮放射治療技術結閤GP化療方案(吉西他濱+順鉑)治療首次放療後跼部複髮的非小細胞肺癌患者的療效.方法:38例首次放療後跼部複髮的非小細胞肺癌患者接受立體定嚮放射治療,處方劑量為3.00~4.85 Gy/次,每週5次,共8~12次,總療程2~3週;放療前基于GP方案化療2箇週期,放療後再給予GP方案化療4箇週期.結果: 38例患者的近期療效為完全緩解7例、部分緩解23例,總有效率達到78.95%,6箇月的總生存率為71.05%,1年的總生存率為10.53%,中位生存時間為7.8箇月.結論:立體定嚮放射治療首次放療後跼部複髮的非小細胞肺癌顯示齣良好的近期療效,患者能夠耐受,未見嚴重的近期放射性損傷.晚期放射性損傷和遠期療效還有待進一步研究.
목적:탐토입체정향방사치료기술결합GP화료방안(길서타빈+순박)치료수차방료후국부복발적비소세포폐암환자적료효.방법:38례수차방료후국부복발적비소세포폐암환자접수입체정향방사치료,처방제량위3.00~4.85 Gy/차,매주5차,공8~12차,총료정2~3주;방료전기우GP방안화료2개주기,방료후재급여GP방안화료4개주기.결과: 38례환자적근기료효위완전완해7례、부분완해23례,총유효솔체도78.95%,6개월적총생존솔위71.05%,1년적총생존솔위10.53%,중위생존시간위7.8개월.결론:입체정향방사치료수차방료후국부복발적비소세포폐암현시출량호적근기료효,환자능구내수,미견엄중적근기방사성손상.만기방사성손상화원기료효환유대진일보연구.
Objective:To study the efficacy of stereotactic radiotherapy (SRT) combined with gemcitabine plus cisplatin (GP)-based chemotherapy on local recurrent non-small-cell lung cancer (NSCLC) after radiotherapy. Methods:Thirty-eight patients with local recurrent NSCLC were treated with SRT(3.00-4.85 Gy per fraction, five times every week, totally 8-12 fractions, total course of 2-3 weeks). Before SRT the patients were given two cycles of GP-based chemotherapy (gemcitabine 1 000 mg/m~2 d 1 and d 8;cisplatin 30 mg/m~2 d 1-3) and at the end of SRT they were given 4 cycles of GP-based chemotherapy. Results:Of the 38 patients,7 patients had complete response, and 23 patients achieved partial response. The overall immediate response rate was 78.95% (30/38). The 6-month and 12-month total survival rates were 71.05% and 10.53%,respectively. The median survival time was 7.8 months. Conclusion:SRT combined with GP-based chemotherapy had better short-term efficacy and the patients were tolerable. No severe short-term radiation-induced injury was observed. The long-term radiation-induced injury and long-term efficacy need further investigation.